Domov › Burkitov lymfóm › Texas › Houston
Klinické štúdie Burkitov lymfóm v meste Houston, TX
21 štúdií pre Burkitov lymfóm hľadá účastníkov v zariadeniach v meste Houston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Prebieha náborFáza 3
- Baylor College Medical Center (Data Collection Only), Houston
- Texas Children's Hospital (Data Collection), Houston
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Prebieha náborFáza 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Prebieha náborFáza 3
- Houston Methodist Hospital, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Prebieha náborObservačná štúdia
- Texas Children's Hospital, Houston
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Prebieha náborFáza 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Prebieha náborFáza 3
- The University of Texas MD Anderson Cancer Center, Houston
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Prebieha náborFáza 1/2
- University of Texas MD Anderson Cancer Center ( Site 1007), Houston
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Prebieha náborFáza 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Prebieha náborFáza 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Prebieha náborFáza 1/2
- Research Site, Houston
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Prebieha náborFáza 2
- Baylor Texas Children's Hospital, Houston
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Prebieha náborFáza 2
- M D Anderson Cancer Center, Houston
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Prebieha náborFáza 1/2
- University of Texas MD Anderson Cancer Center, Houston
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Prebieha náborFáza 1/2
- M D Anderson Cancer Center, Houston
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Prebieha náborFáza 1/2
- Research Site, Houston
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Prebieha náborFáza 2
- M D Anderson Cancer Center, Houston
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Prebieha náborFáza 1
- University of Texas MD Anderson Cancer Center, Houston
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Prebieha náborFáza 1/2
- MD Anderson Cancer Center, Houston
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Prebieha náborFáza 2
- The University of Texas M. D. Anderson Cancer Center, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Prebieha náborFáza 1
- MD Anderson Cancer Center, Houston
Štúdie Burkitov lymfóm v iných mestách
- Philadelphia, PA16 štúdií
- Milwaukee, WI16 štúdií
- Chicago, IL15 štúdií
- Cincinnati, OH13 štúdií
- New York City, NY13 štúdií
- Atlanta, GA12 štúdií
- Aurora, CO11 štúdií
- Seattle, WA11 štúdií
- Durham, NC10 štúdií
- Boston, MA10 štúdií
- Kansas City, MO10 štúdií
- Los Angeles, CA10 štúdií
Iné štúdie v Houston
- Nemalobunkový karcinóm pľúc145 štúdií
- Rakovina prsníka126 štúdií
- Rakovina (všetky typy)121 štúdií
- Metastatická rakovina104 štúdií
- Kolorektálny karcinóm102 štúdií
- Rakovina vaječníkov89 štúdií
- Akútna myeloidná leukémia85 štúdií
- Rakovina pľúc78 štúdií
- Rakovina prostaty76 štúdií
- Rakovina endometria68 štúdií
- Rakovina pankreasu61 štúdií
- Melanóm59 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.